RxDoctor Payments Data

Marcos Benitez, MD

Neurology · Lufkin, TXNPI 1013022979

Payments from drug & device makers

$7,169in general payments, 2019–2025

Across 451 payments — averaging $15.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$1K
  • AbbVie$890
  • Amgen$684
  • Supernus Pharmaceuticals, Inc.$558
  • SK Life Science, Inc.$470
  • UCB, Inc.$414
  • plus $3K from 35 others

What the payments were for

  • Speaking & faculty fees$381%
  • Food & beverage$7,13199%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,169 in reported general payments places this provider in the 60th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$219,059
Medicare patients
230
Services billed
2,094

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RebifInterferon Beta-1a/Albumin13$132,126
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen3,634$107,816
UbrelvyUbrogepant32$37,925
Topiramate ErTopiramate61$25,713
XcopriCenobamate23$25,624
Oxtellar XrOxcarbazepine18$19,873
BriviactBrivaracetam19$19,165
RytaryCarbidopa/Levodopa51$18,745
Aimovig AutoinjectorErenumab-Aooe18$16,053
AptiomEslicarbazepine Acetate13$15,472
TrintellixVortioxetine Hydrobromide30$13,843
Ajovy SyringeFremanezumab-Vfrm17$13,592
Nucynta ErTapentadol Hcl23$13,221
Gabapentin903$11,354
Emgality PenGalcanezumab-Gnlm14$9,869

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
EMD Serono, Inc.Rebif$384$132,12613 claims
AbbVieUbrelvy$890$37,92532 claims
SK Life Science, Inc.Xcopri$470$25,62423 claims
Collegium Pharmaceutical, Inc.Nucynta Er, Belbuca, Xtampza Er$58$23,11747 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$558$19,87318 claims
UCB, Inc.Briviact$414$19,16519 claims
Amneal Pharmaceuticals LLCRytary$275$18,74551 claims
Sunovion Pharmaceuticals Inc.Aptiom$234$15,47213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,246 neurology providers in Texas.

Other neurology in Lufkin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →